- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04414345
HEALEY ALS Platform Trial - Regimen C CNM-Au8
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen C will evaluate the safety and efficacy of a single study drug, CNM-Au8, in participants with ALS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683.
Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.
If a participant is randomized to Regimen C - CNM-Au8, the participant will complete a screening visit to assess additional Regimen C eligibility criteria. Once Regimen C eligibility criteria are confirmed, participants will complete a baseline assessment and be randomized in a 3:1 ratio to either active CNM-Au8 or matching placebo.
Regimen C will enroll by invitation, as participants may not choose to enroll in Regimen C. Participants must first enroll into the Master Protocol and be eligible to participate in the Master Protocol before being able to be randomly assigned to Regimen C.
For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under NCT04297683.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Healey Center for ALS at Mass General
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).
Exclusion Criteria:
The following exclusion criterion is in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).
- History of allergy to gold, gold salts, or colloidal gold preparations.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CNM-Au8
Drug: CNM-Au8 Administration: Oral Dosage: 30 mg or 60 mg daily |
Drug: CNM-Au8 Administration: Oral Dosage: 30 mg or 60 mg daily |
Placebo Comparator: Matching Placebo
Administration: Oral Dosage: 2 bottles daily |
Drug: Matching Placebo Administration: Oral Dosage: 2 bottles daily |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Progression as Assessed by the ALSFRS-R Total Score
Time Frame: Baseline to 24 Weeks
|
Change in disease severity as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) total score using a Bayesian repeated measures model that accounts for loss to follow-up due to mortality.
Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
|
Baseline to 24 Weeks
|
Mortality Event Rate
Time Frame: Baseline to 24 Weeks
|
Mortality is defined as death or death equivalent.
A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row.
The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.
|
Baseline to 24 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory Function
Time Frame: Baseline to 24 Weeks
|
Change in respiratory function as assessed by slow vital capacity (SVC).
|
Baseline to 24 Weeks
|
Muscle Strength
Time Frame: Baseline to 24 Weeks
|
Change in muscle strength as measured isometrically using hand-held dynamometry (HHD).
|
Baseline to 24 Weeks
|
Number of Participants That Experienced Death or Death Equivalent
Time Frame: 24 Weeks
|
The number of participants who died or met the criterion for a death equivalent from the date of their baseline visit to the end of the Week 24visit window (generally 175 days after baseline).
The death equivalent criterion is use of permanent assisted ventilation (PAV) for more than 22hours per day for more than 7 days in a row.
|
24 Weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Merit Cudkowicz, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019P003518C
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amyotrophic Lateral Sclerosis
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
-
University of Sao Paulo General HospitalPontifícia Universidade Católica do ParanáUnknownAMYOTROPHIC LATERAL SCLEROSISBrazil
-
Neuromed IRCCSRecruitingAmyotrophic Lateral Sclerosis (ALS)Italy
-
Humanitas Mirasole SpAKU Leuven; UMC Utrecht; University of Sheffield; Istituto Superiore di Sanità; University... and other collaboratorsActive, not recruitingAmyotrophic Lateral Sclerosis (ALS)United Kingdom, Germany, France, Netherlands, Belgium, Ireland, Italy
-
The Methodist Hospital Research InstituteMassachusetts General Hospital; The Center for Clinical and Translational Sciences... and other collaboratorsActive, not recruiting
-
CytokineticsCompletedAmyotrophic Lateral Sclerosis (ALS)United States, Netherlands, Canada, Belgium, United Kingdom, France, Germany, Ireland, Italy, Portugal, Spain
-
Columbia UniversityALS AssociationTerminatedAmyotrophic Lateral Sclerosis (ALS)United States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedAmyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, SporadicMexico
-
University Hospital, GenevaCompletedAmyotrophic Lateral Sclerosis 11Switzerland
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore MaugeriCompleted
Clinical Trials on CNM-Au8
-
Clene NanomedicineClene Australia Pty LtdTerminatedRelapsing Remitting Multiple Sclerosis | Optic Neuropathy | Optic; Neuritis, With DemyelinationUnited States, Canada, Australia
-
Clene NanomedicineClene Australia Pty LtdCompletedAmyotrophic Lateral SclerosisAustralia
-
Clene NanomedicineUniversity of Texas Southwestern Medical CenterRecruitingMultiple SclerosisUnited States
-
Clene NanomedicineUniversity of Texas Southwestern Medical CenterCompletedParkinson's DiseaseUnited States
-
Clene NanomedicineMassachusetts General HospitalAvailable
-
Clene NanomedicineUniversity of Texas Southwestern Medical CenterWithdrawnAmyotrophic Lateral SclerosisUnited States
-
Clene NanomedicineAvailableAmyotrophic Lateral SclerosisUnited States
-
Clene NanomedicineCompletedHealthy Volunteers - Male and FemaleNetherlands
-
Clene NanomedicineGeorge ClinicalCompletedRelapsing Multiple SclerosisAustralia
-
Merit E. Cudkowicz, MDMassachusetts General HospitalRecruiting